News Release - Eli Lilly and Company
INDIANAPOLIS, May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in …
Alzheimer's Disease | Eli Lilly and Company
We’re taking on Alzheimer’s from every angle: advancing the science that could lead to breakthrough therapies; discovering new ways to find timely and accurate diagnoses; and partnering across our industry and beyond to work with more speed.
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer…
Jul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by...
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
Jun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early...
Eli Lilly’s Alzheimer’s drug slows memory decline, study finds
Jul 17, 2023 · An experimental Alzheimer’s drug from drugmaker Eli Lilly helped slow cognitive decline in patients in the early stages of the illness, according to the results of a late-stage clinical trial.
News Release - Eli Lilly and Company
INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive ...
Eli Lilly trial reveals Alzheimer's drug that significantly slows ...
May 4, 2023 · The pharmaceutical company Eli Lilly announced in a press release on May 3, 2023, that a clinical trial of the experimental Alzheimer's drug, donanemab, showed it could significantly slow the...
Eli Lilly's Alzheimer's Drug Shows Greatest Benefit Yet | TIME
I n a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab.
FDA Approves Eli Lilly’s New Alzheimer’s Treatment - Healthline
Jul 2, 2024 · The U.S. Food and Drug Administration has approved a new drug to treat Alzheimer’s disease. An independent FDA advisory panel endorsed Eli Lilly’s donanemab in June.
Lilly's Alzheimer’s drug that can slow disease gets ... - NBC News
Jun 10, 2024 · A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia...